Loading
A phase 2 trial in pancreatic cancer, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, now recruiting.
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients is a phase 2, interventional study registered as NCT06662006 by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, with a registry enrolment figure of 56 participants, started 2024-03-01 and due to reach its primary completion in 2027-12. Interventions recorded: nal-IRI,5-fu,LV, benmelstobart, anlotinib. Conditions listed: Advanced Metastatic Pancreatic Cancer. Primary outcome: Objective effective rate (ORR). Pancreatic eligibility wording from the registry: "Patients with histologically or cytologically confirmed advanced metastatic pancreatic cancer". Sites: China. No results are recorded here; the registry entry is the source.
Shares SBRT / SABR (stereotactic radiotherapy), Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.